Journal article icon

Journal article

Silencing of Mcl-1 overcomes resistance of melanoma cells against TRAIL-armed oncolytic adenovirus by enhancement of apoptosis

Abstract:
Arming of oncolytic viruses with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has been shown as a viable approach to increase the antitumor efficacy in melanoma. However, melanoma cells may be partially or completely resistant to TRAIL or develop TRAIL resistance, thus counteracting the antitumor efficiency of TRAIL-armed oncolytic viruses. Recently, we found that TRAIL resistance in melanoma cells can be overcome by inhibition of antiapoptotic Bcl-2 protein myeloid cell leukemia 1 (Mcl-1). Here, we investigated whether the cytotoxicity of AdV-TRAIL, an oncolytic adenovirus, which expresses TRAIL after induction by doxycycline (Dox), can be improved in melanoma cells by silencing of Mcl-1. Two melanoma cell lines, the TRAIL-resistant MeWo and the TRAIL-sensitive Mel-HO were investigated. Treatment of both cell lines with AdV-TRAIL resulted in a decrease of cell viability, which was caused by an increase of apoptosis and necrosis. The proapoptotic effects were dependent on induction of TRAIL by Dox and were more pronounced in Mel-HO than in MeWo cells. SiRNA-mediated silencing of Mcl-1 resulted in a further significant decrease of cell viability and a further increase of apoptosis and necrosis in AdV-TRAIL-infected MeWo and Mel-HO cells. However, while in absolute terms, the effects were more pronounced in Mel-HO cells, in relative terms, they were stronger in MeWo cells. These results show that silencing of Mcl-1 represents a suitable approach to increase the cytotoxicity of a TRAIL-armed oncolytic adenovirus in melanoma cells.TU Berlin, Open-Access-Mittel – 202
Publication status:
Published
Peer review status:
Peer reviewed

Actions

Access Document

Authors

More by this author
Role:
Author
ORCID:
0000-0002-1073-7503
More by this author
Role:
Author
ORCID:
0000-0001-8533-1519
More by this author
Institution:
University of Oxford
Role:
Author
ORCID:
0000-0002-8552-2005


More from this funder
Funder identifier:
10.13039/501100005972
Grant:
70112382
70112382


Publisher:
Springer
Journal:
Journal of Molecular Medicine More from this journal
Volume:
99
Issue:
9
Pages:
1279-1291
Publication date:
2021-05-24
DOI:
EISSN:
1432-1440
ISSN:
0946-2716


Language:
English
Keywords:
Pubs id:
1304398
Local pid:
pubs:1304398
Source identifiers:
W3165604347
Deposit date:
2026-04-29
ARK identifier:
This ORA record was generated from metadata provided by an external service. It has not been edited by the ORA Team.

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP